Table 2 Correlation of PD-L1 expression with clinicopathological factors in HER2-positive breast cancer.

From: Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

 

PD-L1 expression

N

p

Negative

Positive

TILs

High

6 (26.1%)

17 (73.9%)

23

<0.0001

Intermediate

34 (91.9%)

3 (8.1%)

37

Low

64 (97.0%)

2 (3.0%)

66

CD8-positive TILs

High

65 (74.7%)

22 (25.3%)

87

0.00087

Low

30 (100.0%)

0 (0.0%)

30

ER

Negative

62 (80.5%)

15 (19.5%)

77

0.45

Positive

42 (85.7%)

7 (14.3%)

49

PgR

Negative

74 (81.3%)

17 (18.7%)

91

0.56

Positive

30 (85.7%)

5 (14.3%)

35

Ki67

High (≥30%)

70 (77.8%)

20 (22.2%)

90

0.36

Low (<30%)

34 (94.4%)

2 (5.6%)

36

Histological grade

Grade 3

85 (79.4%)

22 (20.6%)

107

0.043

Grade 1/2

19 (100.0%)

0 (0.0%)

19

Clinical tumor size

cT 3/4

38 (86.4%)

6 (13.6%)

44

0.41

cT 1/2

66 (80.5%)

16 (19.5%)

82

Clinical nodal status

Positive

68 (80.0%)

17 (20.0%)

85

0.28

Negative

36 (87.8%)

5 (12.2%)

41

  1. Abbreviations: PD-L1, programmed death-ligand 1; TILs, tumor-infiltrating lymphocytes; ER, estrogen receptor; PgR, progesterone receptor HER2, human epidermal growth factor receptor 2.
Back to article page